Kolexia
Berge Yann Oncologie médicale
Berge Yann
Oncologie médicale
Hôpital Jacques Puel - Bourran
Rodez, France
40 Activités
276 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Tumeurs du sein Sarcome du stroma endométrial Léiomyosarcome Sarcome alvéolaire des parties molles Tumeurs des gaines nerveuses Sarcome synovial Liposarcome myxoïde Liposarcome

Collaborateurs

Voir plus
Houyau Philippe
Houyau Philippe
Hôpital Jacques Puel - Bourran, Rodez, France
Alzieu Claude-Pierre
Alzieu Claude-Pierre
Hôpital Jacques Puel - Bourran, Rodez, France
Delord Jean-Pierre
Delord Jean-Pierre
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Auberdiac Pierre
Auberdiac Pierre
Hôpital Jacques Puel - Bourran, Rodez, France

Industries

Voir plus
Ipsen
7 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2023
Merck-Serono
3 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
ADAGE: Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study.
Breast (Edinburgh, Scotland)   07 juin 2019
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
British journal of cancer   16 janvier 2018
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.: An Open Label, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.
Essai Clinique (Roche)   01 novembre 2016
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
British journal of cancer   27 janvier 2015
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
European journal of cancer (Oxford, England : 1990)   18 novembre 2013
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group.
British journal of cancer   06 août 2013
ESTIM-LBH: Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study
Essai Clinique (Centre Léon-Bérard)   05 mars 2013
RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor.
Breast cancer research : BCR   22 janvier 2013
A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors.
2012 ASCO Annual Meeting I   20 mai 2012